Abstract
The mammalian target of rapamycin (mTOR) pathway plays important roles in regulating nutrient metabolism and promoting the growth and survival of cancer cells, which exhibit increased glycolysis for ATP generation. In this study, we tested the hypothesis that inhibition of the mTOR pathway and glycolysis would synergistically impact the energy metabolism in cancer cells and may serve as an effective therapeutic strategy to kill malignant cells. Using human lymphoma cells and leukemia cells, we demonstrated that the combination of rapamycin, an mTOR inhibitor, with a glycolytic inhibitor produced synergistic cytotoxic effect, as evidenced by apoptosis and cell growth inhibition assays. Mechanistic studies showed that inhibition of the mTOR pathway by rapamycin alone sufficiently suppressed the phosphorylation of the downstream molecules p70S6K and 4E-BP-1, but only caused a moderate cytostatic effect. Combination of mTOR inhibition and blockage of glycolysis synergistically suppressed glucose uptake and severely depleted cellular ATP pools, leading to significant enhancement of cell killing. In contrast, combination of rapamycin and ara-C did not increase cytotoxicity in vitro. Our findings suggest that targeting mTOR pathway in combination with inhibition of glycolysis may be an effective therapeutic strategy for hematological malignancies. This mechanism-based drug combination warrants further investigation in preclinical and clinical settings.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Warburg O . The Metabolism of Tumors. London: Constable Co. Ltd, 1930.
Warburg O . On the origin of cancer cells. Science 1956; 123: 309–314.
Zu XL, Guppy M . Cancer metabolism: facts, fantasy, and fiction. Biochem Biophys Res Commun 2004; 313: 459–465.
Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN et al. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 2005; 65: 613–621.
Geschwind JF, Georgiades CS, Ko YH, Pedersen PL . Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma. Expert Rev Anticancer Ther 2004; 4: 449–457.
Maher JC, Krishan A, Lampidis T . Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic condition. Cancer Chemother Pharmacol 2004; 53: 116–122.
Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF et al. 2-Deoxy-D-glucose increases the efficacy of Adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 2004; 64: 31–34.
Ko YH, Pedersen PL, Geschwind JF . Glucose catabolism in the rabbit VX2 model for liver cancer. Cancer Lett 2001; 173: 83–91.
Dennis PB, Jaeschke A, Saitoh M, Fowler B, Kozma SC, Thomas G . Mammalian TOR: a homeostatic ATP sensor. Science 2001; 294: 1102–1105.
Bjornsti MA, Houghton PJ . The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004; 4: 335–348.
Hay N, Sonenberg N . Upstream and downstream of mTOR. Genes Dev 2004; 18: 1926–1945.
Schmelzle T, Hall MN . TOR, a central controller of cell growth. Cell 2000; 103: 253–262.
Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004; 22: 2336–2347.
Panwalkar A, Verstovsek S, Giles FJ . Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 2004; 100: 657–666.
Dancey JE . Inhibitors of the mammalian target of rapamycin. Expert Opin Investig Drugs 2005; 14: 313–328.
Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS et al. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun 2004; 324: 269–275.
Seymour JF, Huang P, Plunkett W, Gandhi V . Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule. Clin Cancer Res 1996; 2: 653–658.
Chou TC, Hayball MP . CalcuSyn: window software for dose effect analysis. Cambridge, United Kingdom: Biosoft.
Easton JB, Houghton PJ . Therapeutic potential of target of rapamycin inhibitors. Expert Opin Ther Targets 2004; 8: 551–564.
Huang L, Shu M, Dilling J, Easton F, Harwood H, Ichijo P et al. Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21Cip1. Mol Cell 2003; 11: 1491–1501.
Edinger AL, Thompson CB . Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol Biol Cell 2002; 13: 2276–2288.
Peterson RT, Desai BN, Hardwick JS, Schreiber SL . Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein. Proc Natl Acad Sci USA 1999; 96: 4438–4442.
Acknowledgements
This study was supported in part by Grants CA85563, CA100428, CA109041, and CA100632 from the National Cancer Institute, the National Institutes of Health.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Xu, RH., Pelicano, H., Zhang, H. et al. Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells. Leukemia 19, 2153–2158 (2005). https://doi.org/10.1038/sj.leu.2403968
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403968
Keywords
This article is cited by
-
Biochemical re-programming of human dermal stem cells to neurons by increasing mitochondrial membrane potential
Cell Death & Differentiation (2019)
-
Glycolysis inhibition via mTOR suppression is a key step in cardamonin-induced autophagy in SKOV3 cells
BMC Complementary and Alternative Medicine (2018)
-
Cell death-based treatment of neuroblastoma
Cell Death & Disease (2018)
-
The anticancer agent 3-bromopyruvate: a simple but powerful molecule taken from the lab to the bedside
Journal of Bioenergetics and Biomembranes (2016)
-
mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling
Apoptosis (2015)